Nutriband Inc. (NASDAQ: NTRB) and Its AVERSA(TM) Platform: A Comprehensive FAQ

What is Nutriband Inc.’s AVERSA(TM) platform?

The AVERSA(TM) platform is Nutriband’s proprietary transdermal system designed to reduce abuse, diversion, and accidental exposure of potent drugs like fentanyl, with patents granted in 46 countries.

Why is the AVERSA(TM) platform significant?

It addresses a critical need for abuse-deterrent drug delivery systems, particularly for opioids like fentanyl, targeting a U.S. sales opportunity of $80M–$200M.

How does Nutriband protect its AVERSA(TM) technology?

Nutriband secures its technology through U.S. trademarks and international patents, including a recent trademark for ‘Nutriband(TM)’ and a patent in Macao, totaling protection in 46 countries.

What is the strategic sports partnership mentioned?

Nutriband has partnered with Charlotte FC to boost brand visibility and community presence, though the content does not detail the partnership’s specifics.

Where can I find more updates about Nutriband Inc.?

Updates are available in the company’s newsroom at https://ibn.fm/NTRB.

What are the implications of Nutriband’s new patents and trademarks?

These intellectual property milestones strengthen Nutriband’s market position and long-term protection for its abuse-deterrent drug delivery technologies.

Who is involved in Nutriband’s development and partnerships?

Nutriband collaborates with the U.S. Patent and Trademark Office, international patent offices, and strategic partners like Charlotte FC, though specific individuals are not mentioned.

When did Nutriband receive its recent U.S. trademark?

Nutriband received a trademark registration from the U.S. Patent and Trademark Office in February, though the exact date is not specified in the content.